Literature DB >> 15723608

Large recursive partitioning analysis of complex disease pharmacogenetic studies. II. Statistical considerations.

Dmitri V Zaykin1, S Stanley Young.   

Abstract

Identifying genetic variations predictive of important phenotypes, such as disease susceptibility, drug efficacy, and adverse events, remains a challenging task. There are individual polymorphisms that can be tested one at a time, but there is the more difficult problem of the identification of combinations of polymorphisms or even more complex interactions of genes with environmental factors. Diseases, drug responses or side effects can result from different mechanisms. Identification of subgroups of people where there is a common mechanism is a problem for diagnosis and prescribing of treatment. Recursive partitioning (RP) is a simple statistical tool for segmenting a population into non-overlapping groups where the response of interest, disease susceptibility, drug efficacy and adverse events are more homogeneous within the segments. We suggest that the use of RP is not only more technically feasible than other search methods but it is less susceptible to multiple-testing problems. The numbers of combinations of gene-gene and gene-environment interactions is potentially astronomical and RP greatly reduces the effective search and inference space. Moreover, the certain reliance of RP on the presence of marginal effects is justifiable as was found by using analytical and numerical arguments. In the context of haplotype analysis, results suggest that the analysis of individual SNPs is likely to be successful even when susceptibilities are determined by haplotypes. Retrospective clinical studies where cases and controls are collected will be a common design. This report provides methods that can be used to adjust the RP analysis to reflect the population incidence of the response of interest. Confidence limits on the incidence of the response in the segmented subgroups are also discussed. RP is a straightforward way to create realistic subgroups, and prediction intervals for the within-subgroup disease incidence are easily obtained.

Entities:  

Mesh:

Year:  2005        PMID: 15723608      PMCID: PMC1467573          DOI: 10.1517/14622416.6.1.77

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  24 in total

1.  Applying data mining techniques to the mapping of complex disease genes.

Authors:  W A Czika; B S Weir; S R Edwards; R W Thompson; D M Nielsen; J C Brocklebank; C Zinkus; E R Martin; K E Hobler
Journal:  Genet Epidemiol       Date:  2001       Impact factor: 2.135

2.  Association studies under general disease models.

Authors:  D M Nielsen; B S Weir
Journal:  Theor Popul Biol       Date:  2001-11       Impact factor: 1.570

3.  Testing association of statistically inferred haplotypes with discrete and continuous traits in samples of unrelated individuals.

Authors:  Dmitri V Zaykin; Peter H Westfall; S Stanley Young; Maha A Karnoub; Michael J Wagner; Margaret G Ehm
Journal:  Hum Hered       Date:  2002       Impact factor: 0.444

4.  Inference on haplotype effects in case-control studies using unphased genotype data.

Authors:  Michael P Epstein; Glen A Satten
Journal:  Am J Hum Genet       Date:  2003-11-20       Impact factor: 11.025

5.  Automated detection of informative combined effects in genetic association studies of complex traits.

Authors:  Nadia Tahri-Daizadeh; David-Alexandre Tregouet; Viviane Nicaud; Nicolas Manuel; François Cambien; Laurence Tiret
Journal:  Genome Res       Date:  2003-08       Impact factor: 9.043

6.  Improved use of SNP information to detect the role of genes.

Authors:  A-S Jannot; L Essioux; M G Reese; F Clerget-Darpoux
Journal:  Genet Epidemiol       Date:  2003-09       Impact factor: 2.135

7.  Genome scans and candidate gene approaches in the study of common diseases and variable drug responses.

Authors:  David B Goldstein; Kourosh R Ahmadi; Mike E Weale; Nicholas W Wood
Journal:  Trends Genet       Date:  2003-11       Impact factor: 11.639

8.  Modeling and E-M estimation of haplotype-specific relative risks from genotype data for a case-control study of unrelated individuals.

Authors:  Daniel O Stram; Celeste Leigh Pearce; Phillip Bretsky; Matthew Freedman; Joel N Hirschhorn; David Altshuler; Laurence N Kolonel; Brian E Henderson; Duncan C Thomas
Journal:  Hum Hered       Date:  2003       Impact factor: 0.444

9.  Use of tree-based models to identify subgroups and increase power to detect linkage to cardiovascular disease traits.

Authors:  Tracy Jennifer Costello; Michael David Swartz; Mahyar Sabripour; Xiangjun Gu; Rishika Sharma; Carol Jean Etzel
Journal:  BMC Genet       Date:  2003-12-31       Impact factor: 2.797

10.  Interval estimation of genetic susceptibility for retrospective case-control studies.

Authors:  Dmitri V Zaykin; Zhaoling Meng; Sujit K Ghosh
Journal:  BMC Genet       Date:  2004-05-11       Impact factor: 2.797

View more
  1 in total

1.  Polymorphic variation in the GC and CASR genes and associations with vitamin D metabolite concentration and metachronous colorectal neoplasia.

Authors:  Elizabeth A Hibler; Chengcheng Hu; Peter W Jurutka; Maria E Martinez; Elizabeth T Jacobs
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-12-05       Impact factor: 4.254

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.